Strategic Collaboration SR-Tiget is a leading gene therapy research institute backed by Fondazione Telethon and Ospedale San Raffaele, with a track record of clinical trials and partnerships, suggesting opportunities to offer research services, translational support, or co-development arrangements with established bioscience entities.

Clinical Translation Strength With over 160 treated patients and three advanced therapy medicines approved, SR-Tiget demonstrates strong translational capabilities and regulatory experience, making them an ideal partner for CRO-like services, GMP process development, and regulatory consulting.

Gene Editing Expertise SR-Tiget has a history of vector design, gene transfer, and gene editing, including CRISPR-based programs; this positions them to procure or co-develop specialized computational biology, vector manufacturing support, and early-access platforms for novel therapies.

Cancer Therapy Expansion Recent focus on applying cell and gene therapy platforms to certain cancers indicates growth potential in oncology collaborations, including joint research initiatives, clinical trial support, and companion diagnostics development opportunities.

Strategic Ecosystem Located within a biomedical campus housing hospitals, a university, and biotech firms, SR-Tiget offers a collaborative ecosystem ideal for multi-partner programs, technology licensing, and joint ventures leveraging shared infrastructure and expertise.